Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma

Yutaka Shimada, Yosuke Hashimoto, Takatsugu Kan, Jun Ichiro Kawamura, Tomoyuki Okumura, Toshiya Soma, Kan Kondo, Naoki Teratani, Go Watanabe, Yoshinori Ino, Michiie Sakamoto, Setsuo Hirohashi, Masayuki Imamura

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Dysadherin is a cancer-associated cell membrane glycoprotein that has been reported to downregulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in metastasis of esophageal squamous cell carcinoma (ESCC), we examined dysadherin and E-cadherin expression in patients with this cancer. Methods: Dysadherin and E-cadherin expression was evaluated in 117 ESCC patients (pT1, 31; pT2, 30; pT3, 39; pT4, 17) by immunohistochemistry. The findings were compared with the clinicopathological data of the patients. Results: Both dysadherin and E-cadherin were localized to the cell membrane. Thirty patients (29.1%) had tumors positive for dysadherin and 41 patients (35.0%) had tumors positive for E-cadherin. Tumors showing dysadherin positivity and negative E-cadherin expression had a significantly worse prognosis than other tumors. When the patients with dysadherinpositive tumors were combined with E-cadherin-negative patients, this group had a worse prognosis (p < 0.0001). Cox multivariate analysis revealed that dysadherin expression was an independent prognostic factor for ESCC (p = 0.003), but E-cadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC. Our results suggested that expression of dysadherin by this cancer may partly explain the poor prognosis of patients with preservation of E-cadherin expression.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalOncology
Volume67
Issue number1
DOIs
Publication statusPublished - 2004

Fingerprint

Cadherins
Neoplasms
Cell Membrane
Esophageal Squamous Cell Carcinoma
Neoplasm Metastasis
Membrane Glycoproteins
Down-Regulation
Multivariate Analysis
Immunohistochemistry

Keywords

  • Cell-cell adhesion
  • E-cadherin
  • Esophageal cancer
  • Lymph node metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shimada, Y., Hashimoto, Y., Kan, T., Kawamura, J. I., Okumura, T., Soma, T., ... Imamura, M. (2004). Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology, 67(1), 73-80. https://doi.org/10.1159/000080289

Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. / Shimada, Yutaka; Hashimoto, Yosuke; Kan, Takatsugu; Kawamura, Jun Ichiro; Okumura, Tomoyuki; Soma, Toshiya; Kondo, Kan; Teratani, Naoki; Watanabe, Go; Ino, Yoshinori; Sakamoto, Michiie; Hirohashi, Setsuo; Imamura, Masayuki.

In: Oncology, Vol. 67, No. 1, 2004, p. 73-80.

Research output: Contribution to journalArticle

Shimada, Y, Hashimoto, Y, Kan, T, Kawamura, JI, Okumura, T, Soma, T, Kondo, K, Teratani, N, Watanabe, G, Ino, Y, Sakamoto, M, Hirohashi, S & Imamura, M 2004, 'Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma', Oncology, vol. 67, no. 1, pp. 73-80. https://doi.org/10.1159/000080289
Shimada Y, Hashimoto Y, Kan T, Kawamura JI, Okumura T, Soma T et al. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology. 2004;67(1):73-80. https://doi.org/10.1159/000080289
Shimada, Yutaka ; Hashimoto, Yosuke ; Kan, Takatsugu ; Kawamura, Jun Ichiro ; Okumura, Tomoyuki ; Soma, Toshiya ; Kondo, Kan ; Teratani, Naoki ; Watanabe, Go ; Ino, Yoshinori ; Sakamoto, Michiie ; Hirohashi, Setsuo ; Imamura, Masayuki. / Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. In: Oncology. 2004 ; Vol. 67, No. 1. pp. 73-80.
@article{739a21645a0042b790c267efe9327d45,
title = "Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma",
abstract = "Objective: Dysadherin is a cancer-associated cell membrane glycoprotein that has been reported to downregulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in metastasis of esophageal squamous cell carcinoma (ESCC), we examined dysadherin and E-cadherin expression in patients with this cancer. Methods: Dysadherin and E-cadherin expression was evaluated in 117 ESCC patients (pT1, 31; pT2, 30; pT3, 39; pT4, 17) by immunohistochemistry. The findings were compared with the clinicopathological data of the patients. Results: Both dysadherin and E-cadherin were localized to the cell membrane. Thirty patients (29.1{\%}) had tumors positive for dysadherin and 41 patients (35.0{\%}) had tumors positive for E-cadherin. Tumors showing dysadherin positivity and negative E-cadherin expression had a significantly worse prognosis than other tumors. When the patients with dysadherinpositive tumors were combined with E-cadherin-negative patients, this group had a worse prognosis (p < 0.0001). Cox multivariate analysis revealed that dysadherin expression was an independent prognostic factor for ESCC (p = 0.003), but E-cadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC. Our results suggested that expression of dysadherin by this cancer may partly explain the poor prognosis of patients with preservation of E-cadherin expression.",
keywords = "Cell-cell adhesion, E-cadherin, Esophageal cancer, Lymph node metastasis",
author = "Yutaka Shimada and Yosuke Hashimoto and Takatsugu Kan and Kawamura, {Jun Ichiro} and Tomoyuki Okumura and Toshiya Soma and Kan Kondo and Naoki Teratani and Go Watanabe and Yoshinori Ino and Michiie Sakamoto and Setsuo Hirohashi and Masayuki Imamura",
year = "2004",
doi = "10.1159/000080289",
language = "English",
volume = "67",
pages = "73--80",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma

AU - Shimada, Yutaka

AU - Hashimoto, Yosuke

AU - Kan, Takatsugu

AU - Kawamura, Jun Ichiro

AU - Okumura, Tomoyuki

AU - Soma, Toshiya

AU - Kondo, Kan

AU - Teratani, Naoki

AU - Watanabe, Go

AU - Ino, Yoshinori

AU - Sakamoto, Michiie

AU - Hirohashi, Setsuo

AU - Imamura, Masayuki

PY - 2004

Y1 - 2004

N2 - Objective: Dysadherin is a cancer-associated cell membrane glycoprotein that has been reported to downregulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in metastasis of esophageal squamous cell carcinoma (ESCC), we examined dysadherin and E-cadherin expression in patients with this cancer. Methods: Dysadherin and E-cadherin expression was evaluated in 117 ESCC patients (pT1, 31; pT2, 30; pT3, 39; pT4, 17) by immunohistochemistry. The findings were compared with the clinicopathological data of the patients. Results: Both dysadherin and E-cadherin were localized to the cell membrane. Thirty patients (29.1%) had tumors positive for dysadherin and 41 patients (35.0%) had tumors positive for E-cadherin. Tumors showing dysadherin positivity and negative E-cadherin expression had a significantly worse prognosis than other tumors. When the patients with dysadherinpositive tumors were combined with E-cadherin-negative patients, this group had a worse prognosis (p < 0.0001). Cox multivariate analysis revealed that dysadherin expression was an independent prognostic factor for ESCC (p = 0.003), but E-cadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC. Our results suggested that expression of dysadherin by this cancer may partly explain the poor prognosis of patients with preservation of E-cadherin expression.

AB - Objective: Dysadherin is a cancer-associated cell membrane glycoprotein that has been reported to downregulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in metastasis of esophageal squamous cell carcinoma (ESCC), we examined dysadherin and E-cadherin expression in patients with this cancer. Methods: Dysadherin and E-cadherin expression was evaluated in 117 ESCC patients (pT1, 31; pT2, 30; pT3, 39; pT4, 17) by immunohistochemistry. The findings were compared with the clinicopathological data of the patients. Results: Both dysadherin and E-cadherin were localized to the cell membrane. Thirty patients (29.1%) had tumors positive for dysadherin and 41 patients (35.0%) had tumors positive for E-cadherin. Tumors showing dysadherin positivity and negative E-cadherin expression had a significantly worse prognosis than other tumors. When the patients with dysadherinpositive tumors were combined with E-cadherin-negative patients, this group had a worse prognosis (p < 0.0001). Cox multivariate analysis revealed that dysadherin expression was an independent prognostic factor for ESCC (p = 0.003), but E-cadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC. Our results suggested that expression of dysadherin by this cancer may partly explain the poor prognosis of patients with preservation of E-cadherin expression.

KW - Cell-cell adhesion

KW - E-cadherin

KW - Esophageal cancer

KW - Lymph node metastasis

UR - http://www.scopus.com/inward/record.url?scp=5644261210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644261210&partnerID=8YFLogxK

U2 - 10.1159/000080289

DO - 10.1159/000080289

M3 - Article

VL - 67

SP - 73

EP - 80

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 1

ER -